Database Update: Pharmaceutical Drug Import to Russia (March 2017)
During the first three months of 2017, Russia imported 113.2 bln RUB worth of ready-made drugs (free circulation prices), which is 8.7% higher than that of the same period of 2016. The in-bulk import has reached 20.6 bln RUB, with an 11.6% increase, which is rather mediocre.
In physical terms, the import of ready-made pharmaceuticals amounted to around 470 mln units, which is only 4.4% higher than that of the same period of 2016. However, the rise was only due to the change of the unit format. Calculated in minimum dosage units (MDU), the dynamics is negative (-9.8%), which is not even compensated by the growing in-bulk imports with a 12% increase.
Despite the mediocre long-term growth rates, the first months of 2017 follow the 2016 trends. However, the long-term growth rates of the import of ready-made drugs in March are excellent, with a 47% increase in monetary terms and 29% in physical terms against February.
Novartis became the leader in the import of ready-made drugs in the first quarter of 2017, with a 14% increase against the same period of 2016 in monetary terms. Sanofi comes seconds, with a 4% decrease. Both companies have increased the in-bulk import, though, by 2.6 and 4 times, respectively. They also import APIs to their own manufacturing sites in Saint Petersburg and the Orlov region.
Read more about pharmaceutical drug import to Russia (February performance) here: http://rncph.com/news/17_03_2017
Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance, RUB (January 2016 – March 2017)